Publications by authors named "Christopher Sorli"

Claim this Profile
E
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
Richard E Pratley, Stephan Jacob, Seungjae Baek, Michael E Trautmann, Marcus Hompesch, Christopher H Sorli

BMJ Open Diabetes Res Care· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E Trautmann, Christopher H Sorli

BMJ Open Diabetes Res Care· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.
Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E Trautmann, Marcus Hompesch, Christopher H Sorli

Diabetes Obes Metab· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
Stefano Del Prato, Jahoon Kang, Michael E Trautmann, John Stewart, Christopher H Sorli

Diabetes Obes Metab· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
Richard E Pratley, Jahoon Kang, Michael E Trautmann, Marcus Hompesch, OakPil Han, Christopher H Sorli

Diabetes Obes Metab· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Julio Rosenstock, Christopher H Sorli, Michael E Trautmann, Cristóbal Morales, Ulrich Wendisch

Diabetes Care· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply.
Christopher Sorli

Lancet Diabetes Endocrinol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl

Lancet Diabetes Endocrinol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dynamic relationship between current and previous severe hypoglycemic events: a lagged dependent variable analysis among patients with type 2 diabetes who have initiated basal insulin.
Michael L Ganz, Qian Li, Neil S Wintfeld, Yuan-Chi Lee, Christopher Sorli

Curr Med Res Opin· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin therapy in type 2 diabetes: a reflection on the state of the art today and the potential journeys yet to come.
Christopher Sorli

Am J Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New developments in insulin therapy for type 2 diabetes.
Christopher Sorli

Am J Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying and meeting the challenges of insulin therapy in type 2 diabetes.
Christopher Sorli, Michael K Heile

J Multidiscip Healthc· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
Christopher Sorli, Mark Warren, David Oyer, Henriette Mersebach, Thue Johansen

Drugs Aging· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes.
Ricardo Vitor Cohen, Manoel Galvão Neto, Jose Luis Correa, Paulo Sakai, Bruno Martins, Christopher Sorli

J Clin Endocrinol Metab· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An analysis of data management tools for diabetes self-management: can smart phone technology keep up?
Elizabeth Ciemins, Patricia Coon, Christopher Sorli

J Diabetes Sci Technol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes.
Leonardo Rodriguez, Eliana Reyes, Pilar Fagalde, Maria Soledad Oltra, Jorge Saba, Christopher Sorli

Diabetes Technol Ther· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis